Showing results (1451-1460 of 1,708) with videos related to
Sort By:
Pageof 171
European Heart Journal Open|August 3, 2022
P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trialsDevika Aggarwal, Kirtipal Bhatia, Zainali S Chunawala, et al.Journal of the American College of Cardiology|September 11, 2024
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHFAnkeet S Bhatt, Deepak L Bhatt, Ph Gabriel Steg, et al.Journal of the American Heart Association|March 9, 2022
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCIBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.Journal of the American College of Cardiology|May 14, 2021
Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI TrialsLawrence A Leiter, Deepak L Bhatt, Darren K McGuire, et al.Nature Medicine|August 6, 2024
Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trialsNicholas A Marston, James P Pirruccello, Giorgio E M Melloni, et al.Lancet (London, England)|March 18, 2015
Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trialsTullio Palmerini, Umberto Benedetto, Letizia Bacchi-Reggiani, et al.Circulation|January 30, 2020
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval StudiesSabato Sorrentino, Bimmer E Claessen, Rishi Chandiramani, et al.Circulation|November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization AnalysesBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.European Heart Journal|October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trialGiulia Magnani, Robert F Storey, Gabriel Steg, et al.European Heart Journal. Quality of Care & Clinical Outcomes|August 24, 2022
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trialAndre Lamy, John Eikelboom, Wesley Tong, et al.Pageof 171